Full text restriction information:Access to this article is restricted until 12 months after publication by request of the publisher.
Restriction lift date:2018-12-15
Citation:Bambury, A., Sandhu, K., Cryan, J. F. and Dinan, T. G. 'Finding the needle in the haystack: systematic identification of psychobiotics', British Journal of Pharmacology, In Press, doi: 10.1111/bph.14127
The brain-gut-microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria which when ingested in adequate amounts confer mental health benefits, are increasingly of interest, as pre-clinical trials continue to show promising results. Particularly in stress related, anxiety and depressive disorders, there is potential for psychobiotics to deliver new therapies. The question of which microbes may prove to be the most promising psychobiotic in delivering such therapies at clinical level is of great importance. Here we look at the characteristics of psychobiotics, in an attempt to present an outline, from which the identification of potential new psychobiotics may be possible.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement